Could a simpler drug strategy make stem cell transplants safer?
NCT ID NCT07188090
Summary
This study is testing a new approach to collecting a patient's own stem cells for a transplant to treat blood cancers like multiple myeloma and lymphoma. The goal is to see if using a standard drug (G-CSF) first and only adding a second drug (Plerixafor) if needed can successfully collect enough stem cells while possibly reducing the risk of a serious complication called engraftment syndrome. The trial will enroll 100 adults to compare this new strategy to older methods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.